ADReCS

Pharmaceutical Information

Drug Name	Alogliptin
Drug ID	BADD_D00079
Description	Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25, 2013.
Indications and Usage	Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Marketing Status	approved
ATC Code	A10BH04
DrugBank ID	DB06203
KEGG ID	D06553
MeSH ID	C520853
PubChem ID	11450633
TTD Drug ID	D0NJ5H
NDC Product Code	64764-250; 45802-087; 66332-7001; 66332-7003; 45802-103; 11532-7001; 71610-300; 64764-125; 64764-625; 11532-7002; 45802-150; 71610-661; 65392-2813; 50090-5574; 66332-7002; 11532-7003
UNII	JHC049LO86
Synonyms	alogliptin \| 2-((6-((3R)-3-aminopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl) benzonitrile \| nesina \| SYR 322 \| SYR322 \| SYR-322

Chemical Information

Molecular Formula	C18H21N5O2
CAS Registry Number	850649-61-5
SMILES	CN1C(=O)C=C(N(C1=O)CC2=CC=CC=C2C#N)N3CCCC(C3)N
Chemical Structure

ADRs Induced by Drug

*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..

ADR Term	ADReCS ID	ADR Frequency (FAERS)	ADR Severity Grade (FAERS)	ADR Severity Grade (CTCAE)
Pemphigoid	23.03.01.004; 10.04.02.002	0.006541%		Not Available
Pemphigus	23.03.01.005; 10.04.02.003	0.000399%		Not Available
Photosensitivity reaction	23.03.09.003	0.001555%
Pruritus	23.03.12.001	0.003988%
Pyrexia	08.05.02.003	0.001396%
Rash	23.03.13.001	0.008176%		Not Available
Rash papular	23.03.13.017	0.001356%		Not Available
Retinopathy	24.03.07.003; 06.10.02.001	0.000399%
Rhabdomyolysis	15.05.05.002	0.001396%
Serum sickness	12.02.08.004; 10.01.03.004	-	-
Skin exfoliation	23.03.07.003	0.000399%		Not Available
Stevens-Johnson syndrome	10.01.01.045; 23.03.01.007; 12.03.01.014; 11.07.01.005	0.000997%
Sudden death	02.03.04.013; 08.04.01.003	0.000399%
Suicide attempt	19.12.01.004	0.000399%
Swollen tongue	23.04.01.014; 10.01.05.015; 07.14.02.003	0.000399%		Not Available
Upper respiratory tract infection	22.07.03.011; 11.01.13.009	-	-
Urticaria	23.04.02.001; 10.01.06.001	0.004188%
Vertigo	17.02.12.002; 04.04.01.003	0.000399%
Vomiting	07.01.07.003	0.004507%
Tubulointerstitial nephritis	20.05.02.002	0.000399%		Not Available
Lung neoplasm malignant	22.08.01.001; 16.19.02.001	0.001196%		Not Available
Prostate cancer	16.25.01.001; 21.04.02.002	0.000598%		Not Available
Hyperinsulinism	14.06.03.007; 05.06.03.007	0.000399%		Not Available
Renal impairment	20.01.03.010	0.000598%		Not Available
Hyperamylasaemia	14.11.01.003	0.000399%		Not Available
Chronic kidney disease	20.01.03.017	0.000877%
Bone marrow failure	01.03.03.005	0.000399%
Drug-induced liver injury	12.03.01.044; 09.01.07.023	0.000798%		Not Available
Biliary obstruction	09.02.02.005	0.000399%		Not Available

The 3th Page First Pre 3 Total 3 Pages